Nathan Rice
Stock Analyst at Piper Sandler
(2.78)
# 2,008
Out of 5,032 analysts
56
Total ratings
45.71%
Success rate
8.45%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MBIN Merchants Bancorp | Maintains: Overweight | $42 → $41 | $30.91 | +32.64% | 8 | Jul 30, 2025 | |
FMBH First Mid Bancshares | Maintains: Overweight | $47 → $49 | $35.53 | +37.91% | 4 | Jul 28, 2025 | |
BFC Bank First | Maintains: Neutral | $115 → $137 | $120.95 | +13.27% | 8 | Jul 21, 2025 | |
BY Byline Bancorp | Reiterates: Overweight | $34 | $26.19 | +29.82% | 8 | Oct 29, 2024 | |
CVS CVS Health | Maintains: Buy | $85 → $74 | $82.52 | -10.32% | 2 | May 2, 2024 | |
NIC Nicolet Bankshares | Assumes: Neutral | $84 | $125.00 | -32.80% | 1 | Jan 10, 2024 | |
ALGN Align Technology | Downgrades: Sell | $197 | $130.45 | +51.02% | 10 | Dec 11, 2023 | |
ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $21.42 | -57.98% | 1 | Apr 25, 2023 | |
IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $635.40 | -31.54% | 4 | Jul 21, 2022 | |
CI The Cigna Group | Initiates: Neutral | $233 | $299.27 | -22.14% | 5 | Dec 14, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $35.27 | +135.33% | 4 | Dec 14, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $17.07 | -12.13% | 1 | Dec 19, 2019 |
Merchants Bancorp
Jul 30, 2025
Maintains: Overweight
Price Target: $42 → $41
Current: $30.91
Upside: +32.64%
First Mid Bancshares
Jul 28, 2025
Maintains: Overweight
Price Target: $47 → $49
Current: $35.53
Upside: +37.91%
Bank First
Jul 21, 2025
Maintains: Neutral
Price Target: $115 → $137
Current: $120.95
Upside: +13.27%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $26.19
Upside: +29.82%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $82.52
Upside: -10.32%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $125.00
Upside: -32.80%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $130.45
Upside: +51.02%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $21.42
Upside: -57.98%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $635.40
Upside: -31.54%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $299.27
Upside: -22.14%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $35.27
Upside: +135.33%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $17.07
Upside: -12.13%